Steward Partners Investment Advisory LLC Has $2.25 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

29 Nov 2025, 06:06 by Scott Moore · The Cerbat Gem

Steward Partners Investment Advisory LLC trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 20.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,286 shares of the biopharmaceutical company’s stock after selling 1,082 shares during the quarter. Steward Partners Investment Advisory LLC’s holdings in Regeneron Pharmaceuticals were worth $2,250,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Activest Wealth Management lifted its position in shares of Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 21 shares during the period. Costello Asset Management INC acquired a new position in Regeneron Pharmaceuticals during the first quarter worth $27,000. Saudi Central Bank bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at $27,000. Colonial Trust Advisors bought a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth about $32,000. Finally, SouthState Corp increased its position in shares of Regeneron Pharmaceuticals by 550.0% during the 1st quarter. SouthState Corp now owns 52 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 44 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Christine A. Poon sold 6,500 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on REGN shares. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a report on Tuesday, September 2nd. Morgan Stanley reduced their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating on the stock in a research report on Friday, October 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $757.91.

Check Out Our Latest Research Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $779.09 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The firm has a market cap of $81.88 billion, a price-to-earnings ratio of 18.66, a PEG ratio of 2.03 and a beta of 0.31. The company’s fifty day simple moving average is $634.75 and its 200 day simple moving average is $583.43. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $800.99.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping the consensus estimate of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period last year, the company posted $12.46 EPS. On average, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

About Regeneron Pharmaceuticals

(Free Report)